(134 days)
Not Found
No
The device description details a rapid immunochromatographic assay based on antibody binding and visual line interpretation, with no mention of computational analysis, algorithms, or learning processes.
No
The device is an immunochromatographic assay intended for the qualitative detection of Clostridium difficile toxins, which is used as an aid in diagnosis, not for treatment.
Yes
Explanation: The "Intended Use / Indications for Use" section states that "This test is intended as an aid in the diagnosis of C. difficile-associated disease (CDAD) in patients with symptoms of CDAD." This directly indicates its role in diagnosis.
No
The device description clearly states it is an immunochromatographic assay using physical test sticks and pipettes to detect substances in a stool sample. This involves physical components and chemical reactions, not just software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "qualitative detection of Clostridium difficile toxins A and/or B in human stool samples" and is "intended as an aid in the diagnosis of C. difficile-associated disease (CDAD) in patients with symptoms of CDAD." This clearly indicates it's used to examine specimens derived from the human body to provide information for diagnostic purposes.
- Device Description: The description details a test that analyzes a human sample (stool) using a chemical/biological reaction (immunochromatographic assay) to detect specific substances (C. difficile toxins A and B).
- Anatomical Site: The test is performed on "Human stool samples."
- Performance Studies: The document describes clinical performance studies comparing the device's results to a reference method (cytotoxicity assay) using human stool samples.
All of these points align with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The OSOM C. difficile Toxin A/B Test is an immunochromatographic assay intended for the qualitative detection of Clostridium difficile toxins A and/or B in human stool samples. This test is intended as an aid in the diagnosis of C. difficile-associated disease (CDAD) in patients with symptoms of CDAD.
Product codes (comma separated list FDA assigned to the subject device)
LLH
Device Description
The OSOM C. difficile Toxin A/B Test is a rapid test which can detect the presence of Clostridium difficile toxins A and B in human stool samples. A test kit contains 25 OSOM test stick devices and 25 disposable pipettes. The OSOM C. difficile Toxin A/B Test is a qualitative assay that employs immunochromatographic, dipstick technology. The test format is a sandwich immunoassay, with a single test zone on the nitrocellulose dipstick to detect Toxin A and/or Toxin B ("blue/gray" line) and a single control line zone to indicate proper sample flow ("red" line). The test procedure involves binding of C. difficile Toxin A and/or Toxin B from a patient stool sample to blue colored latex particles conjugated to a monoclonal antibody against Toxin B or a polyclonal antibody against Toxin A. When Toxin A and/or B is present in the sample, it will form a partial immune complex with the antibody-conjugated colored particles. The OSOM C. difficile Toxin A/B Test stick, when placed in the sample mixture, initiates sample migration along the nitrocellulose membrane. If C. difficile toxin A or toxin B is present, a blue/gray line will appear in the test line region indicating a positive result. A red control line must appear for the results to be valid. If C. difficile toxins are not present, only the red control line will appear. An invalid test occurs when no control line appears.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
18 years or older
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
A clinical trial was conducted at five sites in the United States to establish the clinical sensitivity and clinical specificity of the OSOM C. difficile Toxin A/B Test in detecting Clostridium difficile toxins A and/or B in human stool samples. De-identified excess loose or watery stool specimens were obtained from patients at or over the age of 18 years whose stool specimen had been submitted to the laboratory for C. difficile-associated disease (CDAD) testing. Specimens were tested with the OSOM C. difficile Toxin A/B Test within 72 hours of receipt. The cytotoxicity assay was performed at Genzyme using a standard C. difficile toxin cytotoxicity assay. Those performing the cytotoxicity assay testing were blinded to the OSOM test results.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical Performance: A clinical trial (study type) was conducted at five sites in the United States. Sample size: 1274 specimens. Standalone performance: Sensitivity: 88.2% (95% CI, 80.5 - 93.1%), Specificity: 96.8% (95% CI, 95.7 - 97.7%), Agreement: 96.2% (95% CI, 95.1 - 96.9%). Key results: The overall sensitivity, specificity and accuracy of the OSOM test compared to cytotoxicity assay are shown in Table 2.
Performance of OSOM C. difficile Toxin A/B Test and the Predicate Device Compared to Cytotoxicity Assay:
The performance of the OSOM C. difficile Toxin A/B Test and a commercially available predicate device were compared to cytotoxicity assay results (see Table 3). All immunoassay device testing was performed at a clinical trial site. A total of 250 paired sample results (OSOM and Predicate Device) were included in this comparison. The performance of the Predicate Device and OSOM tests were compared to the results from the cytotoxicity assay.
OSOM C. difficile Toxin A/B Test: Sensitivity: 87.5% (42/48; 95% CI, 75.3 - 94.1%) Specificity: 90.1% (182/202; 95% CI, 85.2 - 93.5%).
Predicate Device: Sensitivity: 70.8% (34/48; 95% Cl, 56.8 - 81.8%) Specificity: 97.5% (197/202; 95% Cl, 94.3 - 98.9%).
Analytical Sensitivity: The OSOM C. difficile Toxin A/B Test detected 15 ng/mL for Toxin A and 40 ng/mL Toxin B. These studies were conducted with three representative lots of the OSOM C. difficile Toxin A/B Test using a serial dilution series prepared from purified C. difficile toxin A and toxin B in a buffer matrix.
Cross-Reactivity: The OSOM C. difficile Toxin A/B Test was evaluated with bacterial and viral isolates. All testing was performed in a diarrhea matrix except where noted. Cross-reactivity testing was performed with materials obtained from ATCC. Bacterial isolates were tested at a concentration of 10° cfu/mL except where noted. All viruses were cultured to ensure viability and tested at the specified concentrations. All bacteria listed gave negative responses. All viruses listed produced negative responses.
Interfering Substances: The following potential interferents were tested and were found to have no effect on the performance of the OSOM C. difficile Toxin A/B Test: Barium sulfate, Fecal fat, Hemorrhoidal Cooling Gel, Imodium® AD caplets, Kaopectate®, KY Jelly, Metronidazole, Mucin, Pepto Bismol®, Vancomycin, Whole blood.
Reproducibility: Reproducibility studies were performed by two laboratory personnel per day at two external clinical laboratories and one internal site, on a coded panel that contained synthetic stool samples representing both negative and positive C. difficile Toxin A and Toxin B samples. Testing occurred twice per day over a period of 5 days for 120 total test results for each of the three sites. Each operator tested a coded panel of 12 samples: 3 negative samples, 3 high negative samples, 3 low positive samples and 3 moderate positive samples. The OSOM C. difficile Toxin A/B Test gave the expected result 99.2% (357/360) of the time.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity: 88.2% (95% CI, 80.5 - 93.1%)
Specificity: 96.8% (95% CI, 95.7 - 97.7%)
Agreement: 96.2% (95% CI, 95.1 - 96.9%)
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.2660 Microorganism differentiation and identification device.
(a)
Identification. A microorganism differentiation and identification device is a device intended for medical purposes that consists of one or more components, such as differential culture media, biochemical reagents, and paper discs or paper strips impregnated with test reagents, that are usually contained in individual compartments and used to differentiate and identify selected microorganisms. The device aids in the diagnosis of disease.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
0
510(k) Summary of Safety and Effectiveness Section 5.
This 510(k) summary of safety and effectiveness is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is:K102242
Sponsor/Applicant Name and Address 1.
| Company Name: | Genzyme Diagnostics |
|---|---|
| Address: | 31 New York Avenue |
| Framingham, MA 01701-9322 | |
| Telephone: | 508-661-1154 |
| Contact Person: | Carol C. Ryerson |
| Director, Regulatory Affairs | |
| Date Summary Prepared: | 08/05/2010 |
- Device Name and Classification
| Trade Name: | OSOM C. difficile Toxin A/B Test |
|---|---|
| Classification of Device: | 21 CFR 866.2660 Microorganism |
| differentiation and identification device; | |
| reagents, Clostridium difficile toxin | |
| Product Code: | LLH |
| Classification: | Class I |
1
3. Predicate Device
K041951 – Remel Xpect® Clostridium difficile Toxin A/B
Device Description 4.
The OSOM C. difficile Toxin A/B Test is a rapid test which can detect the presence of Clostridium difficile toxins A and B in human stool samples. A test kit contains 25 OSOM test stick devices and 25 disposable pipettes. The OSOM C. difficile Toxin A/B Test is a qualitative assay that employs immunochromatographic, dipstick technology. The test format is a sandwich immunoassay, with a single test zone on the nitrocellulose dipstick to detect Toxin A and/or Toxin B ("blue/gray" line) and a single control line zone to indicate proper sample flow ("red" line). The test procedure involves binding of C. difficile Toxin A and/or Toxin B from a patient stool sample to blue colored latex particles conjugated to a monoclonal antibody against Toxin B or a polyclonal antibody against Toxin A. When Toxin A and/or B is present in the sample, it will form a partial immune complex with the antibody-conjugated colored particles. The OSOM C. difficile Toxin A/B Test stick, when placed in the sample mixture, initiates sample migration along the nitrocellulose membrane. If C. difficile toxin A or toxin B is present, a blue/gray line will appear in the test line region indicating a positive result. A red control line must appear for the results to be valid. If C. difficile toxins are not present, only the red control line will appear. An invalid test occurs when no control line appears.
5. Intended Use
The OSOM C. difficile Toxin A/B Test is an immunochromatographic assay intended for the qualitative detection of Clostridium difficile toxins A and/or B in human stool samples. This test is intended as an aid in the diagnosis of C. difficile-associated disease (CDAD) in patients with symptoms of CDAD.
2
Comparison to Predicate Device 6.
The Table below provides a summary of the device characteristics for the OSOM C. difficile Toxin A/B Test and the predicate device.
| Device Characteristics | OSOM C. difficile
Toxin A/B Test
[New Device] | Remel Xpect C. difficile
Toxin A/B test
[Predicate/ K041951] |
|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use | An immunochromatographic
assay intended for the qualitative
detection of Clostridium difficile
toxins A and/or B in human stool
samples. Intended as an aid in
the diagnosis of Clostridium
difficile-associated disease
(CDAD) in patients with
symptoms of CDAD. | A rapid in vitro
immunochromatographic test for
the direct, qualitative detection
of Clostridium difficile Toxin A
and/or B in human fecal
specimens from patients
suspected of having Clostridium
difficile-associated disease
(CDAD). Intended for use as an
aid in diagnosis of CDAD. |
| Specifically detecting: | Qualitative C. Difficile
Toxin A/B | Qualitative - C. Difficile
Toxin A/B |
| Specimen | Human fecal specimen | Human fecal specimen |
| Assay Method | Immunochromatographic
dipstick technology | Immunochromatographic
membrane assay |
| Antibodies | Capture: goat polyclonal anti-
Toxin A and rabbit polyclonal
anti-Toxin B
Detection: goat polyclonal anti-
Toxin A and mouse monoclonal
anti-Toxin B | Capture: mouse anti-Toxin A and
rabbit anti-Toxin B
Detection: Biotinylated goat anti-
Toxin A and rabbit anti-Toxin B |
| Sample Volume | Solid stool: pea-sized portion
using applicator stick provided
Liquid stool: 0.05 mL | Solid stool: 0.2g
Liquid stool: 0.2 mL |
| Assay Time | 20 minutes | 20 minutes |
Table 1: Comparison of Technological Characteristics of Genzyme OSOM C. difficile Toxin A/B Test with Legally Marketed Device
3
7. Summary of Performance Data
Clinical Performance. A clinical trial was conducted at five sites in the United States to establish the clinical sensitivity and clinical specificity of the OSOM C. difficile Toxin A/B Test in detecting Clostridium difficile toxins A and/or B in human stool samples. Qualitative results obtained using the OSOM C. difficile Toxin A/B Test were compared with those determined by cytotoxicity assay.
De-identified excess loose or watery stool specimens were obtained from patients at or over the age of 18 years whose stool specimen had been submitted to the laboratory for C. difficileassociated disease (CDAD) testing. Specimens were tested with the OSOM C. difficile Toxin A/B Test within 72 hours of receipt. The cytotoxicity assay was performed at Genzyme using a standard C. difficile toxin cytotoxicity assay. Those performing the cytotoxicity assay testing were blinded to the OSOM test results.
The total incidence rate observed in this study for C. difficile associated disease (CDAD) based on the cytotoxicity assay results was 8.0% (102/ 1274). The overall sensitivity, specificity and accuracy of the OSOM test compared to cytotoxicity assay are shown in the table below.
| Cytotoxin | ||||
|---|---|---|---|---|
| + | - | Total | ||
| OSOM® | ||||
| C. difficile | ||||
| Toxin A/B | ||||
| Test | + | 90 | 37 | 127 |
| - | 12 | 1135 | 1147 | |
| Total | 102 | 1172 | 1274 | |
| Sensitivity: $90/102 = 88.2%$ (95% CI, 80.5 - 93.1%) | ||||
| Specificity: $1135/1172 = 96.8%$ (95% CI, 95.7 - 97.7%) | ||||
| Agreement: $1225/1274 = 96.2%$ (95% CI, 95.1 - 96.9%) |
| Table 2: OSOM C. difficile Toxin A/B Test Performance vs. Cytotoxicity Assay |
|---|
| ------------------------------------------------------------------------------ |
Discrepant testing was performed with a commercially available PCR-based molecular method which detects the tcdB gene. Note this PCR method does not detect biologically active protein or Toxin A gene. Twelve of twelve specimens that were cytotoxin positive and OSOM C. difficile
4
Toxin A/B negative were positive for the presence of tcdB gene. Of the 37 specimens that were cytotoxin negative and OSOM C. difficile Toxin A/B positive, 30 of 36 were negative for the tcdB gene, 6 were positive for the tcdB gene, 1 specimen was not available for testing by PCR.
Performance of OSOM C. difficile Toxin A/B Test and the Predicate Device Compared to Cytotoxicity Assay .
The performance of the OSOM C. difficile Toxin A/B Test and a commercially available predicate device were compared to cytotoxicity assay results (see Table 3). All immunoassay device testing was performed at a clinical trial site. A total of 250 paired sample results (OSOM and Predicate Device) were included in this comparison. The performance of the Predicate Device and OSOM tests were compared to the results from the cytotoxicity assay.
Table 3: Performance of OSOM C. difficile Toxin A/B Test and a Commercially Available Lateral Flow Assay Compared to Cytotoxicity Assay (CTA)
| Cytotoxin | Total | |||
|---|---|---|---|---|
| + | - | |||
| OSOM C. | ||||
| difficile Toxin | ||||
| A/B Test | + | 42 | 20 | 62 |
| - | 6 | 182 | 188 | |
| Total | 48* | 202 | 250 |
- 1 sample gave an invalid OSOM test result with the frozen sample - no internal control line appeared even on repeat; included in the analysis as an incorrect result for purposes of comparison.
| Cytotoxin | Total | |||
|---|---|---|---|---|
| ﺔ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤ | + | |||
| Predicate | + | 34 | 5 | રૂત્વે |
| Device | 14 | 197 | 211 | |
| Total | 48 | 202 | 250 |
Sensitivity: 87.5% (42/48; 95% CI, 75.3 - 94.1%) Specificity: 90.1% (182/202; 95% CI, 85.2 - 93.5%)
Sensitivity: 70.8% (34/48; 95% Cl, 56.8 - 81.8%) tal Specificity: 97.5% (197/202; 95% Cl, 94.3 - 98.9%)
5
Analytical Sensitivity. The OSOM C. difficile Toxin A/B Test detected 15 ng/mL for Toxin A and 40 ng/mL Toxin B. These studies were conducted with three representative lots of the OSOM C. difficile Toxin A/B Test using a serial dilution series prepared from purified C. difficile toxin A and toxin B in a buffer matrix.
- Cross-Reactivity. The OSOM C. difficile Toxin A/B Test was evaluated with bacterial and viral isolates. All testing was performed in a diarrhea matrix except where noted. Cross-reactivity testing was performed with materials obtained from ATCC. Bacterial isolates were tested at a concentration of 10° cfu/mL except where noted. All viruses were cultured to ensure viability and tested at the specified concentrations. All bacteria listed gave negative responses. All viruses listed produced negative responses.
6
| Aeromonas hydrophila | Escherichia coli |
|---|---|
| Bacillus cereus | Escherichia coli sero:0157 |
| Bacillus subtilis | Escherichia coli type 0124:NM (ETEC) |
| Bacteroides fragilis | Escherichia coli type o78:k80:h12 (EIEC) |
| Campylobacter coli | Giardia lamblia2 |
| Campylobacter fetus | Helicobacter pylori |
| Campylobacter jejuni | Klebsiella pneumoniae |
| Candida albicans | Peptostreptococuss anaerobius |
| Clostridium difficile (non-toxigenic) | Porphyromonas asaccharolytica |
| Clostridium beijerinckii | Proteus vulgaris |
| Clostridium haemolyticum | Pseudomonas aeruginosa |
| Clostridium histolyticum | Salmonella typhimurium |
| Clostridium novyi | Serratia liquefaciens |
| Clostridium perfringens3 | Shigella dysenteriae2 |
| Clostridium septicum | Shigella flexneri |
| Clostridium sordellii | Shigella sonnei |
| Clostridium sporogenes | Staphylococcus aureus (Cowan's serotype 1) |
| Clostridium tetani | Staphylococcus aureus |
| Cryptosporidium parvum1 | Staphylococcus epidermidis |
| Enterobacter aerogenes | Vibrio cholerae3 |
| Enterobacter cloacae | Vibrio parahaemolyticus |
| Enterococcus faecalis | Yersinia enterocolitica |
Table 3: Organisms tested at 10° cfu/mL except where noted
l Tested at 0.91x106 cfu/mL
² Tested at 1 x 10⁶ cfu /mL
2 Tested at 1x10* cfu /mL
3 Tested 1x10* cfu /mL in a buffer matrix
| TCID50/mL | |
|---|---|
| Human adenovirus 40 (strain Dugan) | 5.25x104 |
| Human coxsackievirus B4 (strain J.V.B) | 2.34x104 |
| Human cytomegalovirus (strain Towne) | 1.86x102 |
| Human echovirus 22 (strain Harris) | 4.79x106 |
| Human enterovirus 69 (strain Toluca – 1) | 9.55x104 |
| Human rotavirus (strain HRV-408) | 1.62x102 |
| Table 4: Viruses tested at specified concentrations |
|---|
| ----------------------------------------------------- |
7
Interfering Substances. The following potential interferents were tested and were found to have no effect on the performance of the OSOM C. difficile Toxin A/B Test.
| Potential Interferent | Concentration |
|---|---|
| Barium sulfate | 5% w/v |
| Fecal fat | 5% w/v |
| Hemorrhoidal Cooling Gel | 5% v/v |
| Imodium® AD caplets | 5% w/v |
| Kaopectate® | 5% v/v |
| KY Jelly | 5% v/v |
| Metronidazole | 0.25% w/v |
| Mucin | 3.5% w/v |
| Pepto Bismol® | 5% v/v |
| Vancomycin | 0.25% w/v |
| Whole blood | 40% v/v |
Table 5: Exogenous Substances
Reproducibility. Reproducibility studies were performed by two laboratory personnel per day at two external clinical laboratories and one internal site, on a coded panel that contained synthetic stool samples representing both negative and positive C. difficile Toxin A and Toxin B samples. Testing occurred twice per day over a period of 5 days for 120 total test results for each of the three sites. Each operator tested a coded panel of 12 samples: 3 negative samples, 3 high negative samples, 3 low positive samples and 3 moderate positive samples. The OSOM C. difficile Toxin A/B Test gave the expected result 99.2% (357/360) of the time.
8
8. Conclusion
The information presented in this Premarket Notification demonstrates the performance of the OSOM C. difficile Toxin A/B Test for use with human stool samples is substantially equivalent in intended use, technological characteristics, and performance to the predicate device, thereby supporting 510(k) clearance.
Equivalence was demonstrated using manufactured reagents along with patient and quality control samples containing C. difficile toxins A and B.
The studies in this submission demonstrate the substantial equivalence of the OSOM C. difficile Toxin A/B Test to products already marketed for the qualitative detection of Clostridium difficile in human stool specimens.
9
Image /page/9/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal features a stylized eagle with its wings spread, symbolizing the agency's mission to protect and promote the health and well-being of all Americans. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle, indicating the agency's name and national scope. The seal is simple and recognizable, representing the HHS's role in public health and human services.
Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993
Genzyme Diagnostics c/o Ms. Carol C. Ryerson Director, Regulatory Affairs 31 New York Avenue Framingham, MA 01701-9322
DEC 2 1 250
Re: K102242
Trade/Device Name: OSOM C. difficile Toxin A/B Test Regulation Number: 21 CFR 866.2660 Regulation Name: Microorganism differentiation and identification device Regulatory Class: Class I Product Code: LLH Dated: December 8, 2010 Received: December 9, 2010
Dear Ms. Ryerson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent ffor the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000
10
Page 2 - Carol C. Ryerson
electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Valla, aAr
Sally A. Hojvat, M.Sc., Ph.D Director Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
11
Indications for Use
DEC 2 1 2010
510(k) Number (if known): _ K102242
OSOM C. difficile Toxin A/B Test Device Name:
Indications For Use:
The OSOM C. difficile Toxin A/B Test is an immunochromatographic assay intended for the qualitative detection of Clostridium difficile toxins A and/or B in human stool samples. This test is intended as an aid in the diagnosis of C. difficile-associated disease (CDAD) in patients with symptoms of CDAD.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Raguel Peat acting Associate Director
Division Sign-Off for Freddie Poole
Office of In Vitro Diagnostic Device Evaluation and Safety
Page 1 of 1
K102242 ﺔ ﺍﻟﻤﺮﺍﺟﻊ